Study Reveals Tumor with More Mutations Respond Better to Immunotherapy

Immunotherapy TrialsiteN

In a recent study mutational data from 1,662 patients with advanced cancer who were treated with checkpoint inhibitor therapy were studied as well as data from 5,000 patients who were not treated with this therapy—but it was found that the mutation data was available.  Published in Nature Genetics, the new study suggests that tumors with more mutations respond better to immunotherapy. Immune checkpoint inhibitors including the following:

  • Tecentriq (atezolizumab)
  • Bavencio (avelumab)
  • Imfinzi (durvalumab)
  • Yervoy (ipilimumab)
  • Opidivo (nivolumab)
  • Keytruda (pembrolizumab) or Tremelimumab